HIF HIF Prolyl-Hydroxylase

HIF HIF Prolyl-Hydroxylase

HIFs (Hypoxia-inducible factors) are transcription factors that react to variations in the amount of oxygen available to cells, more specifically, to reductions in oxygen, or hypoxia. The effects of hypoxia, a condition of low oxygen concentration, on the cell are mediated by the HIF signaling cascade. Oftentimes, hypoxia prevents cells from differentiating. However, hypoxia encourages the growth of blood vessels and is crucial for the development of a vascular system in both cancer tumors and embryos.Additionally, the hypoxia in wounds encourages keratinocyte migration and epithelium repair. HIFs are essential to development in general. HIF-1 gene deletion in mammals causes perinatal death. It has been demonstrated that HIF-1 is essential for chondrocyte survival and enables the cells to adapt to low oxygen environments in the growth plates of bones. Human metabolism is controlled in large part by HIF. A number of medications that function as selective HIF prolyl hydroxylase inhibitors have recently been created.

HIF HIF Prolyl-Hydroxylase related products

Structure Cat No. Product Name CAS No. Product Description
V73839 ML228 analog 1357026-36-8 ML228 analog is the analog of ML228.
V2958 Molidustat 1154028-82-6 Molidustat (formerly known as BAY 85-3934) is a novel potent inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) which stimulates erythropoietin (EPO) production and the formation of red blood cells.
V51639 Moracin O 123702-97-6 Moracin O comes from Morus alba Linn.
V51640 Moracin P 102841-46-3 Moracin P is a 2-arylbenzoepoxy resin extracted from Mori Cortex Radicis.
V51625 Naphthofluorescein (Naphthafluorescein) 61419-02-1 Naphthylfluorescein inhibits the response between HIF-1 and Mint3.
V51642 OHM-1 1450995-09-1 OHM1 is an analog of HIF1α CTAD and inhibits its binding to p300/CBP.
V51622 Oltipraz-d3 2012598-51-3 Oltipraz-d3 is a labeled substitute for Oltipraz.
V30464 Oroxylin A 480-11-5 Oroxylin A is an active flavonoid compound with strong anti-cancer effects.
V73835 PHD-IN-1 2924182-31-8 PHD-IN-1 (compound 80) is a potent PHD2 inhibitor (antagonist) with IC50 ≤5 nM.
V73836 PHD-IN-2 2924182-42-1 PHD-IN-2 (Compound 91) is a PHD antagonist (IC50= <5 nM).
V73837 PHD2-IN-1 2768219-28-7 PHD2-IN-1 is a potent, orally bioactive HIF-prolyl hydroxylase 2 (PHD2) inhibitor (antagonist) with IC50 of 22.53 nM for anemia research.
V4090 PT-2385 1672665-49-4 PT2385 (PT-2385) is a nove, potent, selective and orally bioactive inhibitor of hypoxia inducible factor (HIF-2α) with anticancer and anti-hepatic steatosis activity.
V51634 Steppogenin 56486-94-3 Steppogenin is a potent HIF-1α and DLL4 replacement with IC50s of 0.56 and 8.46 μM, respectively.
V51623 TAT-cyclo-CLLFVY 1446322-66-2 TAT-cyclo-CLLFVY is a HIF-1 heterodimeric cyclic peptide conjugate that can inhibit regulatory hypoxia signaling activation.
V81522 TAT-cyclo-CLLFVY TFA TAT-cyclo-CLLFVY TFA is a cyclic peptide inhibitor of HIF-1 heterodimerization that can inhibit hypoxia signaling in cancer cells.
V51621 TRC-160334 1293289-69-6 TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor.
V5246 Vadadustat (PG-1016548; AKB-6548) 1000025-07-9 Vadadustat (formerly AKB-6548;PG-1016548; B-506;AKB6548;PG1016548;Vafseo) is a novel, potent, titratable and orally bioavailable hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor with the potential for the treatment of anemia.
V51624 Verucopeptin 138067-14-8 Verucopeptin is a potent activator of HIF-1 (IC50=0.22 μM) and can reduce the expression of HIF-1 target genes and the expression level of HIF-1α.
V51004 WAY-325641 869354-47-2 HIV-1 integrase inhibitor
V73833 Zifcasiran sodium (ADS-007 sodium; ARO HIF2 sodium) 2437257-12-8 Zifcasiran sodium is a hypoxia-inducible factor (HIF) synthesis inhibitor and displays anti-tumor activity and may be utilized in the study of advanced renal cell carcinoma.
Contact Us Back to top